In a surprising finding that suggests radical changes in the way prostate cancer is managed, researchers at the University of Chicago Medical Center have shown in laboratory experiments that the male hormone testosterone, which fuels prostate cancers early in their growth, can in later stages cause tumors to stop growing or even shrink.
The finding is reported in the October 15 issue of the Proceedings of the National Academy of Sciences.
Doctors have routinely used surgical or chemical castration to slow the growth of cancer that has spread beyond the gland since 1941, when University of Chicago urologist Charles Huggins showed that prostate cancers require testosterone for growth and demonstrated the effectiveness of removing the hormone. Huggins received the Nobel Prize for this work in 1966.
Men treated with antihormone therapy often show dramatic improvement. But within a few years, the tumors regrow because the cells lose their dependency on testosterone and are able to thrive without it.
Now a researcher who was a colleague of Huggins for more than 30 years has shown that those tumors that no longer depend on testosterone may, in fact, be sensitive to it. Shutsung Liao, phd, professor in the Ben May Institute for Cancer Research, and coworkers showed in laboratory mice that testosterone can shrink experimental human prostate tumors that no longer depend on the hormone.
The finding suggests that testosterone supplementation, perhaps delivered by a patch, may be beneficial for certain types of prostate cancer, and that prolonged use of antihormone drugs, like leuprolide (Lupron), goserelin(Drug information on goserelin) (Zoladex), and finasterid (Proscar) should no longer be routine.
Interesting Preliminary Finding
"This is an interesting preliminary finding that may make us rethink our approach to therapy," said Glenn Gerber, md, a University of Chicago urologist not connected to the study.
Prostate cancer is the most commonly diagnosed cancer in American men, with 317,000 new cases and 41,400 deaths expected in 1996. Although several treatment options are available for cancers confined to the gland, only antihormone therapy has been effective for slowing the growth of distant tumors.
"Although three-quarters of prostate cancer patients can have their tumors shrunk by castration or anti-hormone drug therapy, most of these cancers recur in 1 to 3 years and are then no longer dependent on hormones," Liao said. "Currently, once the tumor becomes independent of testosterone, there is no way to treat it."
Standard chemotherapy agents are not very effective against prostate cancer. The goal, according to Gerber, is to improve long-term management of the disease.
"While this new approach is not likely to cure anyone," said Gerber, "it suggests that we may be able to restart the survival clock, perhaps several times, not just by starving cells that need testosterone but also by feeding it to cells that gag on it."
To simulate the recurrence of hormone-independent cancer, research associate John Kokontis grew human prostate cancer cells in the laboratory and weaned them off testosterone, a process that required repeated re-culturing of the cells over a 2-year period. These cells, now capable of growing testosterone-free, were used to seed tumors in laboratory mice. The researchers looked at the effect of testosterone on these mice compared to mice implanted with tumors that need testosterone.
The researchers found that adding even low levels of testosterone could shrink established tumors of hormone-independent cells. Removing the added testosterone, or adding testosterone-lowering drugs, caused the tumors to regrow.
The researchers dedicated the report to Huggins, who turned 95 last month and has been in ill health. The work was funded by the National Institutes of Health.
Authors of the report in addition to Liao and Kokontis are visiting professor Yoshihisa Umekita and senior research associate Richard Hiipakka.